Dihydroartemisinin Sensitizes Mutant p53 (R248Q)-Expressing Hepatocellular Carcinoma Cells to Doxorubicin by Inhibiting P-gp Expression

Dihydroartemisinin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cell by Upregulating Tumor Necrosis Factor via JNK/NF-κB Pathways

(2019) Long Wu et al.   Evidence-based Complementary and Alternative Medicine

Enhancing the Efficacy and Safety of Doxorubicin against Hepatocellular Carcinoma through a Modular Assembly Approach: The Combination of Polymeric Prodrug Design, Nanoparticle Encapsulation, and Cancer Cell-Specific Drug Targeting

(2018) Li Xu et al.   ACS Applied Materials & Interfaces

Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation

(2018) Xiaohui Yan et al.   BIOCHEMICAL PHARMACOLOGY

Advances in Studies of P-Glycoprotein and Its Expression Regulators

(2018) Kentaro Yano et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Dihydroartemisinin induced caspase-dependent apoptosis through inhibiting the specificity protein 1 pathway in hepatocellular carcinoma SK-Hep-1 cells

(2018) Eunji Im et al.   LIFE SCIENCES

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dihydroartemisinin Increases the Sensitivity of Photodynamic Therapy Via NF-κB/HIF-1α/VEGF Pathway in Esophageal Cancer Cell in vitro and in vivo

(2018) Yanjing Li et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers

(2017) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy

(2017) Xuetian Yue et al.   JOURNAL OF MOLECULAR BIOLOGY

Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway

(2017) Hong Jin et al.   Molecular Medicine Reports

Census and evaluation of p53 target genes

(2017) M Fischer   ONCOGENE

Systemic Therapy for Hepatocellular Carcinoma: 2017 Update

(2017) Masatoshi Kudo   ONCOLOGY

p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo

(2017) Evguenia M Alexandrova et al.   Cell Death & Disease

Mechanistic diversity in ATP-binding cassette (ABC) transporters

(2016) Kaspar P Locher   NATURE STRUCTURAL & MOLECULAR BIOLOGY

SH3GL1 inhibition reverses multidrug resistance in colorectal cancer cells by downregulation of MDR1/P-glycoprotein via EGFR/ERK/AP-1 pathway

(2016) Haitao Guan et al.   TUMOR BIOLOGY

Mechanistic diversity in ATP-binding cassette (ABC) transporters

(2016) Kaspar P Locher   NATURE STRUCTURAL & MOLECULAR BIOLOGY

The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation

(2016) S M D K Ganga Senarathna et al.   PLoS One

Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells

(2015) Guiqi Qin et al.   APOPTOSIS

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient

(2015) Nataly Shtraizent et al.   International Journal of Environmental Research and Public Health

Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches

(2014) Qiong Wu et al.   CANCER LETTERS

Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity

(2014) Sanna R Rijpma et al.   MALARIA JOURNAL

Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor

(2013) Jerson L. Silva et al.   BIOSCIENCE REPORTS

Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo

(2012) Chris Zhiyi Zhang et al.   BIOCHEMICAL PHARMACOLOGY

Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance

(2012) K. G. Chen et al.   CLINICAL CANCER RESEARCH

Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma

(2012) Hashem B. El-Serag   GASTROENTEROLOGY

Mutant p53: one name, many proteins

(2012) W. A. Freed-Pastor et al.   GENES & DEVELOPMENT

Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-κB modulation

(2012) Jun Lee et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature

(2012) Hilla Solomon et al.   JOURNAL OF CELL SCIENCE

Clitocine Reversal of P-Glycoprotein Associated Multi-Drug Resistance through Down-Regulation of Transcription Factor NF-κB in R-HepG2 Cell Line

(2012) Jianguo Sun et al.   PLoS One

Functional Significance of Genetic Polymorphisms in P-glycoprotein (MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2)

(2011) Ichiro Ieiri   Drug Metabolism and Pharmacokinetics

Multiple Drug Resistance Mechanisms in Cancer

(2010) Bruce C. Baguley   MOLECULAR BIOTECHNOLOGY

Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action

(2008) J. Hou et al.   CLINICAL CANCER RESEARCH

Qinghaosu (Artemisinin): The Price of Success

(2008) N. J. White   SCIENCE